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Objective: We tested a unique new device, the Myosplint device (Myocor, Inc,
Maple Grove, Minn), which is designed to change left ventricular shape, reduce left
ventricular wall stress, and improve left ventricular systolic function.
Methods: Heart failure was induced in 15 dogs over 27 days by rapid pacing (230
beats/min). Seven animals underwent sham surgery, and 8 animals received 3 trans-
ventricular Myosplint devices each. Myosplint devices were tightened to create a
symmetric bilobular left ventricular shape and were adjusted to produce a calculat-
ed 20% reduction in wall stress. Hemodynamic, 2-dimensional, and 3-dimensional
echocardiographic studies were recorded at baseline, immediately after Myosplint
placement (acute change), and at 1 month after both groups had a reduced rate (190
beats/min) of pacing designed to maintain heart failure.
Results: The Myosplint group had significant sustained improvements in left ven-
tricular ejection fraction from baseline, to the acute change, to 1 month (19% ± 5%;
36% ± 8%; 39% ± 13%) and reductions of left ventricular end-systolic volumes (73
± 9 mL; 34 ± 5 mL; 42 ± 12 mL) and end-systolic wall stress by 39% (341 ± 68 103
dynes · cm– 2 to 206 ± 28 103 dynes · cm–2) acutely and 31% (372 ± 83 103 dynes
· cm–2 to 250 ± 40 103 dynes · cm–2) at 1 month. There were no significant changes
in mitral regurgitation.
Conclusion: Application of a Myosplint device to a dilated impaired left ventricle
resulted in reduced wall stress and improved left ventricular systolic function that
was sustained at 1 month. Device-based shape change is a promising new opportu-
nity to treat patients with dilated cardiomyopathy.
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Acommon theme in the progression andpathogenesis of heart failure is the devel-opment of left ventricular (LV) remodel-ing with cardiac decompensation.1,2 Theremodeled LV geometry creates dilata-tion, increased LV sphericity, and wall
thinning. Physiologic disadvantages created by LV remod-
eling include increased LV wall stress, increased myocardial
oxygen consumption, and episodic subendocardial hypoper-
fusion. Increased LV wall stress may lead to the expression
of stretch-activated genes with worsening compensatory
mechanisms including further dilation, myocyte hypertro-
phy, and interstitial fibrosis.
The Batista procedure, or partial left ventriculectomy,
reduced the size of the pathologically remodeled LV and
improved LV systolic function and early subjective and
objective measurements of heart failure.3-5 However, the
operation fell into disfavor in large measure because of a
high early failure rate associated with the morbidity of the
invasive and complex LV resection and reconstruction.6 We
sought a solution to the mechanical disadvantages of patho-
logic LV remodeling that could be applied easily without
cardiopulmonary bypass, that improved global LV function
without removing a large segment of otherwise viable LV
muscle, and that would have a low procedure-related and
device-related morbidity.
A novel device, the Myosplint device (Myocor, Inc,
Maple Grove, Minn), was developed to change LV shape,
decrease LV wall stress, and improve LV function and effi-
ciency. The purposes of this article are (1) to introduce the
thought process behind this unique concept, (2) to describe
the current generation of the device, and (3) to review the
experimental studies to prove the concept.
Methods 
The Myosplint Concept
The Myosplint device consists of an implantable transventricular
splint and two epicardial pads that are adjusted to draw the walls
of the LV together and thereby reduce the LV radius. The
Myosplint is positioned to bisect the enlarged LV, effectively cre-
ating two smaller LV chambers. According to the law of Laplace
for cylindrical chambers, circumferential wall stress is directly
proportional to LV radius, R1 (Figure 1). The law of Laplace sim-
plifies the stress modeling difficulties associated with biologic
material properties and complex geometries. The relationship
assumes that stresses are uniform across the wall and around the
LV circumference and are due exclusively to chamber pressure.
With the use of the same assumptions about material properties
and stress distribution, equilibrium formulas can be developed and
a stress relationship derived for the mid-chamber annular region of
the splinted bilobular chamber (two cylinders). The derivation
yields the formula T = PR2/h, where T is wall stress, P is chamber
pressure, and R2 is the reduced effective radius of the bilobular
chamber. This equation provides a useful approximation for cir-
cumferential wall stress and has correlated well with significantly
more complex finite element modeling.
The concept can be easily and intuitively understood by an
analogy to two persons comfortably holding a sail in a strong wind,
as described in Figure 2.
Ventricular shape change is achieved by the placement of 3
Myosplints bisecting the LV with epicardial pads that disperse
some of the force over the epicardium. The devices are adjusted
to reduce LV wall stress by 20%. This reduction level is based
on simple calculations from LV end-diastolic diameter measured
by a specially designed measuring/tightening device. The
Myosplints are placed on the beating heart with a device that
precisely places the Myosplint to avoid epicardial vessels, pap-
illary muscles, and the mitral valve apparatus. A variety of posi-
tions are possible, but the most common position was from the lat-
eral wall (just lateral to the anterior papillary muscle) to the posterior
septum. This position was chosen because of ease of insertion and the
ability to avoid epicardial and intraventricular structures (Figure 3).
Myosplint Design
The Myosplint device consists of two main components. The first is
a 1.4-mm diameter polyethylene braided splint coated with expand-
ed polytetrafluoroethylene. This tension member is connected to the
second component, the epicardial pads. The pads are covered with
polyester fabric and constructed from high-performance engineering
thermoplastic. One pad is permanently fixed to the splint, and anoth-
er similar adjustable epicardial pad is threaded over and fixed to the
splint after implantation. All of these biomaterials have a history of
use in human implants. In particular, the blood-contacting expanded
polytetrafluoroethylene splint coating has been extensively investi-
Figure 1. The law of Laplace explains the increased wall stress
(T) in the dilated heart that is directly related to the radius (R1) and
intraventricular pressure (P) and, inversely, by wall thickness (h).
The splinted chamber creates a modified bilobular shape. Wall
stress now is directly proportional to the reduced radius of each
lobe (R2).
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gated in other cardiovascular applications such as mitral valve chord
replacement or vascular grafts. The braided polyethylene tension
member is extremely durable, as evidenced by its freedom from
structural deterioration at 200 million cycles (5 years) of accelerated
life testing. Furthermore, this material has proven equally resistant to
hydraulic degradation as well as creep. To facilitate implantation of
the Myosplint on a beating heart, a specially designed “C-device” has
also been developed. This device allows for gentle stabilization of the
heart during the procedure, as well as precise delivery of the device.
Development Phase, in Vivo Experimental Work, and
Current in Vivo Study
A number of factors were addressed in the initial development of
the device and the experimental model. The initial work was per-
formed as acute experiments, in dogs with normal LV function,
using a variety of biomaterials for the Myosplint device, and
devices were developed to place the Myosplints and measure the
amount of shape change. The concept was then tested in short-term
experiments with pacing-induced models of heart failure.7 Also,
echocardiographic and hemodynamic studies of the complex shape
change effects were undertaken,8 eventually leading to the use of
3-dimensional (3-D) echocardiographic studies. Finally, a model
of maintenance heart failure with reduced pacing rates was devel-
oped,9 after the initial model led to the death of approximately
50% of control animals before the 30-day end point. 
After this developmental work, the device design and materials
were frozen and the following in vivo study was undertaken. The
hypotheses of this study are that (1) the Myosplint device will
reduce LV wall stress, (2) the device will improve LV systolic
function, and (3) these changes will be sustained at 1 month in this
canine model of pacing-induced heart failure. The study was
approved by the institutional animal care committee, and all ani-
mals received humane care in compliance with the “Guide for the
Care and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, National Research Council, and
published by the National Academy Press, revised 1996. 
Induction of heart failure, baseline measurements, and
surgery. Twenty-seven adult mongrel dogs (body weight 26.4 ±
1.4 kg) were paced into heart failure as per previous studies.10,11
The animals were anesthetized with thiopental (15 mg/kg), intu-
bated, and the anesthesia was maintained with isoflurane (0.5%-
2.5%). Under sterile conditions, a bipolar pacemaker lead
(Medtronic 4068; Medtronic, Inc, Minneapolis, Minn) was placed
in the right ventricle via the right jugular vein. This was connected
to a pulse generator (Medtronic 8086) and buried in a subcuta-
neous cervical pocket. The animal received antibiotics for 5 days.
After a minimum of 2 days of recovery, rapid asynchronous ven-
tricular pacing at 230 beats/min was used for an average of 27 ± 4
days to induce heart failure. No medications for heart failure,
including diuretics, were given during the heart failure induction
phase. During this phase, the animal was under careful daily obser-
vation for signs or symptoms of congestive heart failure.
Figure 2. The concept of the Myosplint device can best be understood by conceiving of two people holding a sail.
A, In a strong wind, two people are able to comfortably hold a small sail. B, However, if the size of the sail is
increased, and all other factors are kept constant, the two people feel an increased amount of tension. C, With the
increased force, the two people are pushed back until they engage a post that changes the shape of the sail and
absorbs some of the force. D and E, To complete the concept, the wind is equivalent to LV pressure, the post of the
sail is equivalent to the Myosplint effecting shape change, and the tension that the two people feel is equivalent
to wall stress. Therefore, the enlarged ventricle will have reduced wall stress after splinting.
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At the conclusion of the induction phase, transthoracic 2-dimen-
sional (2-D) echocardiograms were obtained during temporary
resumption of normal sinus rhythm to evaluate the progression of
cardiac remodeling, the reduction of LV function, and the develop-
ment of mitral and tricuspid regurgitation. A total of 7 animals were
excluded from the study at this point because ejection fraction was
greater than 35% (n = 4) or mitral regurgitation was 4+ (n = 3).
On the date of study, the pacemaker was reduced to demand mode
at 30 beats/min so that the animal would resume normal sinus
rhythm, and the animal was placed under general anesthesia as pre-
viously described. A catheter with two Millar pressure sensors
(model SPC-562; Millar Instruments, Inc, Houston, Tex) was placed
via the carotid artery to record aortic and LV pressures. A thermistor-
tip balloon catheter (Criticath SP5507 TD catheter; Becton Dickinson
Infusion Therapy Systems Inc, Sandy, Utah) was passed from the
jugular vein to the pulmonary artery to monitor the pulmonary artery
pressure, pulmonary capillary wedge pressure, and the central venous
pressure. Cardiac output (CO) was measured by the thermodilution
method, and stroke volume (SV = CO/[Heart rate]) and stroke work
(SW = SV × [LV systolic pressure – LV end-diastolic pressure] ×
0.0136) were calculated. These hemodynamic measurements were
recorded as baseline closed chest. Hemodynamic indices were digi-
tized in real time at a sampling rate of 200 Hz with a data acquisition
system (PowerLab; AD Instruments, Inc, Mountain View, Calif) and
stored on a hard disk for subsequent complete analysis. Ventilatory
support was transiently stopped during data acquisition periods. An
additional 3 dogs were excluded from the study with mild heart fail-
ure defined as central venous pressure less than 8 mm Hg and pul-
monary capillary wedge pressure less than 13 mm Hg.
To most accurately assess the changes in LV volumes and ejection
fractions before and after LV shape change, we used a 3-D ultrasound
system (Volumetrics Medical Imaging Inc, Durham, NC).
Transthoracic 3-D images were obtained in real time and stored in a
digital format. Subsequently, LV end-diastolic and end-systolic vol-
umes were determined by rotated apical 6-plane views with a multi-
planar Simpson method.12 Stroke volume (SV3D = LV end-diastolic
volume – LV end-systolic volume), stroke work (SW3D = SV3D ×
[LV systolic pressure – LV end-diastolic pressure] × 0.0136), cardiac
output (CO3D = SV3D × Heart rate), and LV ejection fraction
(SV3D/LVEDV × 100) were calculated. Transthoracic 2-D images
were obtained to assess mitral and tricuspid regurgitation by color
flow Doppler imaging and to measure wall thickness and LV dimen-
sions at various levels. 
Circumferential end-systolic and end-diastolic wall stresses
were calculated from the 2-D echocardiogram short-axis view at
the papillary muscle level in combination with LV pressure using
the following formula: Wall stress = 1.33 × LV pressure × (LV
radius)/h, where h is wall thickness.13,14 After implantation of the
Myosplint device, the 2-D short-axis view showed two symmetric
lobes; one consisted of the anteroseptal wall and the other consist-
ed of the posterolateral wall, as shown in Figure 3. The wall stress
of each lobe was calculated separately using the radius and the
wall thickness of each lobe; then the two values were averaged.
Implant surgery, heart failure maintenance, and 1-month stud-
ies. After acquisition of closed chest baseline data (Tables 1 and 2;
baseline, closed chest), a sternotomy incision was made and the chest
was opened. Hemodynamic, 2-D, and 3-D echocardiographic mea-
surements were repeated (Tables 1 and 2; baseline, open chest).
Dogs were enrolled in the study as control or test (Myosplint-
treated) on the basis of device availability and alternate assign-
ment. Eight animals served as controls and were observed for 45
minutes (the estimated time of Myosplint implantation and mea-
surements). Their chests were closed, and the animals recovered in
intensive care after all monitoring catheters had been removed.
Nine animals received 3 Myosplint devices each. There were no
arrhythmias or bleeding complications during implantation. The
Figure 3. Three transventricular splints are placed to bisect the ventricle (far left), and epicardial pads are used
to tighten the Myosplint device to the desired diameter (upper right). Echocardiography (bottom right) demon-
strates the bisected bilobular LV shape change.
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appropriate location for Myosplint implantation was guided by
epicardial 2-D echocardiogram to avoid the mitral valve structures
and by direct visualization to avoid epicardial vessels. The first
Myosplint device was placed 2 cm from the atrioventricular groove
and the next two were spaced approximately 2 cm apart toward the
LV apex (Figure 3).
Each Myosplint device was then tightened to draw the LV walls
inward creating a symmetric, bilobular LV. The tightening level
was adjusted to produce a calculated 20% reduction in wall stress
determined by the pre-tightening LV end-diastolic diameter. In
other words, the radius of each lobe of the LV was approximately
80% of the radius of the pre-tightened LV. Ten minutes after tight-
ening, hemodynamic and echocardiographic measurements were
repeated (Tables 1 and 2; acute change, open chest). The chest was
then closed.
Animals in both groups were treated the same; analgesics and
antibiotics were administered, but no anticoagulants or antiplatelet
drugs were administered. After the animals recovered from the oper-
ation, 3 days after the operation, rapid ventricular pacing at a
reduced rate, 190 beats/min, was resumed. This was maintained for
4 weeks and prevented the recovery of LV function with pacing ces-
sation11 but allowed a more controlled maintenance of congestive
heart failure so that the animals survived until study completion.
Animals were carefully observed daily. A 40-mg dose of furosemide
was given daily to both groups of animals because of fluid overload
noted in the control animals in the developmental phase of the study.
One control animal died with signs of pneumonia, pleural effusion,
and ascites on the seventh postoperative day. One test animal was put
to death on the 20th postoperative day because of pacing failure.
Consequently, 8 test and 7 control animals were included in the sta-
tistical analysis as shown in Tables 1 and 2.
At the completion of the follow-up period, the animals were
anesthetized as per the previous studies and hemodynamic moni-
toring lines were replaced. Then, 2-D and 3-D echocardiographic
studies were repeated (Tables 1 and 2; 4 weeks, closed chest). The
animals were killed with sodium phenobarbital (100 mg/kg) and
potassium chloride (80 mEq). A complete autopsy was performed,
and tissues from the heart, liver, spleen, kidneys, and lungs were
taken for histologic examination.
Statistical Analysis
Data were expressed as mean ± SD. For the test animals, there
were two pairs of data: open chest data (baseline and acute change)
for acute evaluation and closed chest data (baseline and chronic
change) for chronic evaluation. For the control animals, there was
one pair of data: closed chest data (baseline and chronic change)
for chronic evaluation. A paired t test was used for each paired
data. For the comparison between the test and control groups, an
unpaired t test was used.
Results
By 3-D echocardiographic calculations, LV ejection frac-
tion significantly increased from 19% at baseline (closed
chest) to 36% (P = .001) acutely and remained at 39% (P
= .005) at 1 month (Figure 4) after Myosplint implanta-
tion. Also, LV end-diastolic and end-systolic volumes sig-
TABLE 1. Echocardiographic findings
Test group (n = 8) Control group (n = 7)
Baseline: Baseline: Acute: 4 Weeks: Baseline: 4 Weeks: 
closed chest open chest open chest  closed chest  closed chest closed chest
3-D echo findings ( n = 7)
LVEDV (mL) 90.4 ± 13.3 87.1 ± 12.6 54.1 ± 9.2†† 67.9 ± 12.8**‡‡ 104.3 ± 16.2 119.8 ± 19.4
LVESV (mL) 73.0 ± 8.5 69.4 ± 9.2 34.1 ± 5.2†† 41.9 ± 12.1**‡‡ 79.6 ± 19.6 95.2 ± 24.6
SV3D (mL) 17.4 ± 6.2§ 17.7 ± 6.1 20.0 ± 5.9 26.0 ± 9.8 24.7 ± 6.2 24.7 ± 9.9
SW3D (g · m) 17.7 ± 7.2§ 15.7 ± 5.9 17.8 ± 5.2 29.6 ± 10.7* 28.1 ± 11.1 30.8 ± 17.9
CO3D (L/min) 1.98 ± 0.74 1.71 ± 0.62 1.93 ± 0.62 3.80 ± 1.54** 2.85 ± 0.83 3.48 ± 1.47
LVEF (%) 18.7 ± 5.3 20.0 ± 5.9 36.4 ± 7.6†† 38.8 ± 13.4**‡ 24.6 ± 8.6 21.4 ± 10.3
2-D echo findings
MR (º) 1.9 ± 0.7 2.1 ± 0.6 2.1 ± 0.4 1.7 ± 0.9 1.9 ± 0.7 1.6 ± 0.8
TR (°) 1.9 ± 1.0 2.8 ± 0.8 2.4 ± 0.9† 1.2 ± 0.9 2.1 ± 0.7 2.1 ± 1.2
ESWS (103 dynes · cm–2) 372 ± 83 341 ± 68 206 ± 28†† 250 ± 40**‡‡ 375 ± 39 350 ± 75
EDWS (103 dynes · cm–2) 127 ± 53 107 ± 39 76 ± 33†† 74 ± 36** 123 ± 52 91 ± 58*
LVEDV, LV end-diastolic volume; LVESV, LV end-systolic volume; SV3D, LV stroke volume calculated by LVEDV and LVESV; SW3D, LV stroke work calculat-
ed by SV3D and LV pressures; CO3D, cardiac output calculated by SV3D and heart rate; LVEF, ejection fraction; MR, mitral regurgitation; TR, tricuspid regur-
gitation; ESWS, LV end-systolic wall stress; EDWS, LV end-diastolic wall stress.
*P < .05 versus baseline (closed chest). 
**P < .01 versus baseline (closed chest).
†P < .05 versus baseline (open chest).
††P < .01 versus baseline (open chest).
‡P < .05 versus 4 weeks (closed chest) in control group.
‡‡P < .01 versus 4 weeks (closed chest) in control group.
§P < .05 vs baseline (closed chest) in control group.
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nificantly decreased (Table 1) and were sustained at 1
month. End-systolic wall stress significantly decreased by
39% (341 ± 68 103 dynes · cm–2 to 206 ± 28 103 dynes ·
cm–2; P < .0001) acutely and by 31% (372 ± 83 103 dynes
· cm–2 to 250 ± 40 103 dynes · cm–2; P = .003) at 1 month
(Figure 5). Also, end-diastolic wall stress was significant-
ly reduced by 30% (107 ± 39 103 dynes · cm–2 to 76 ± 33
103 dynes · cm–2; P = .002) acutely and by 41% (127 ± 53
103 dynes · cm–2 to 74 ± 36 103 dynes · cm–2; P = .006)
chronically. Among those parameters, only the reduction
(by 29%; P = .02) in end-diastolic wall stress was signif-
icant in the control group. There were no significant
chronic changes in either the test or control groups
regarding mitral or tricuspid regurgitation (Table 1).
There were significant reductions at 1 month in both
groups in mean pulmonary artery pressure and LV end-dia-
stolic pressure. The reduction in pulmonary artery pressure
and LV end-diastolic pressure probably reflects the addition
of furosemide and reduced pacing rate. Central venous pres-
sure significantly decreased in the test group. Pulmonary
capillary wedge pressure significantly decreased in the con-
trol group. There were also significant increases at 1 month
in both groups in heart rate and absolute value of minimum
rate of change of LV pressure.
No change in cardiac output was measured by the ther-
modilution method from baseline to 4 weeks in the test or
control animals. However, cardiac output calculated from 3-
D echocardiographic volumes significantly increased from
baseline to 4 weeks (1.98 ± 0.74 L/min to 3.80 ± 1.54
L/min; P = .008) in the test animals. Similarly, although
there was no change in stroke work calculated by thermo-
dilution cardiac output from baseline to 4 weeks in the test
or control animals, 3-D stroke work calculated from 3-D
echocardiographic volumes significantly increased (17.7 ±
7.2 g · m to 29.6 ± 10.7 g · m; P = .04) in the test animals.
Hypertrophy of the cardiac myofibers, interstitial edema,
and mild interstitial fibrosis was present in all animals. The
gross necropsy revealed that the epicardial pads become
rapidly encapsulated in fibrous tissue. At a histologic level,
the anticipated foreign body response to the biomaterials
used was observed: a proliferation of fibroblasts and
macrophages, coupled with the presence of occasional for-
eign body giant cells. Overall, we judged this a normal
chronic wound healing response in the presence of foreign
material. There was no evidence of toxic or neoplastic
response to the device. Fibrous encapsulation and endothe-
lialization were observed around the intraventricular portion
of the device. Thrombi at the LV apex were observed in 6
control and 3 test animals. Their location and presence in
both groups suggest that they are related to the placement of
the Millar catheter in a nonheparinized subject. Examination
of downstream organs revealed the limited presence of
TABLE 2.  Hemodynamics
Test group (n = 8) Control group (n = 7)
Baseline: Baseline: Acute: 4 Weeks: Baseline: 4 Weeks: 
closed chest open chest open chest closed chest closed chest closed chest
HR (beats/min) 115 ± 14 96 ± 7 95 ± 7 146 ± 16** 116 ± 20 142 ± 15**
CO (L/min) 2.20 ± 0.43 1.79 ± 0.40 2.02 ± 0.21 2.51 ± 0.89 2.09 ± 0.31 2.26 ± 0.64
SV (mL) 19.4 ± 4.6 18.7 ± 4.5 21.4 ± 2.6 17.1 ± 5.8 18.5 ± 4.0 16.0 ± 4.0
LVPsys (mm Hg) 104 ± 17 87 ± 12 88 ± 9 108 ± 14 109 ± 13 108 ± 21
LVPed (mm Hg) 28.1 ± 9.2 22.0 ± 6.4 22.2 ± 6.8 23.0 ± 10.5* 28.6 ± 9.5 22.2 ± 12.2*
SW (g · m) 19.5 ± 2.8 16.4 ± 4.4 19.2 ± 3.7 20.2 ± 9.3 20.5 ± 7.1 19.1 ± 7.1
dP/dtmax (mm Hg/s) 1156 ± 273 845 ± 169 921 ± 143 1409 ± 378 1155 ± 224 1260 ± 362
dP/dtmin (mm Hg/s) –1123 ± 158 –836 ± 139 –982 ± 172† –1723 ± 404** –1229 ± 242 –1642 ± 328**
AoPm (mm Hg) 92 ± 16 70 ± 22 75 ± 9 96 ± 14 97 ± 9 97 ± 20
SVR (dyne · s · cm–5) 3175 ± 1053 2770 ± 1159 2711 ± 616 3141 ± 872 3480 ± 513 3358 ± 941
PAPm (mm Hg) 29.1 ± 9.9 20.9 ± 6.1 22.6 ± 5.3 20.9 ± 8.8* 30.0 ± 12.7 22.7 ± 13.0*
PVR (dyne · s · cm–5) 268 ± 77 354 ± 211 229 ± 188†† 168 ± 78** 254 ± 105 237 ± 131
PCWP (mm Hg) 21.7 ± 8.4 16.3 ± 5.3 18.0 ± 4.5 16.0 ± 8.0 23.5 ± 11.6 16.6 ± 11.5*
CVP (mm Hg) 8.4 ± 2.7 8.4 ± 3.9 7.8 ± 3.2 4.8 ± 2.4* 7.3 ± 4.3 5.7 ± 3.4
HR, Heart rate off pacing; CO, cardiac output measured by thermodilution; SV, stroke volume measured by thermodilution; LVPsys, LV systolic pressure;
LVPed, LV end-diastolic pressure; SW, LV stroke work calculated by SV and LV pressures; dP/dtmax, maximum positive rate of change of LV pressure;
dP/dtmin, minimum negative rate of change of LV pressure; AoPm, mean aortic pressure; SVR, systemic vascular resistance; PAPm, mean pulmonary arte-
rial pressure; PVR, pulmonary vascular resistance; PCWP, pulmonary capillary wedge pressure; CVP, central venous pressure.
*P < .05 versus baseline (closed chest).
**P < .01 versus baseline (closed chest).
†P < .05 versus baseline (open chest).
††P < .01 versus baseline (open chest).
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infarction or emboli: kidney (2 control and 1 test animals),
lung (1 control and 1 test animals), and liver (1 test animal)
that segregated into no particular group.
Discussion
The dilated, impaired, remodeled LV is a poor prognostic
sign indicating a high mortality in both medically and sur-
gically treated patients.15,16 Medical therapy, such as
angiotensin-converting enzyme inhibitors and β-blockers,
have shown a reduction in mortality associated with a reduc-
tion in LV size and increase in LV ejection fraction.17-19
These subjective and objective improvements, as well as
reduction in mortality, with medical therapy are usually not
from an increase in cardiac output,17-19 indicating that their
effectiveness rests on fundamental changes in the heart fail-
ure milieu.1,2,18
The salutary effects of the Myosplint device in this
experimental study, a significant reduction in wall stress and
volumes and a significant increase in ejection fraction, also
were accomplished without a major change in thermodilu-
tion cardiac output. In the current understanding of heart
failure, cardiac output has assumed less importance, which
explains why some outpatients with compensated conges-
tive heart failure have a cardiac index of 1.8 L · min–2 · m–2
and some hospitalized end-stage inotrope-dependent
patients have a cardiac index of 2.4 L · min–1 · m–2.1,2 By 3-
D echocardiogram, however, stroke work and cardiac output
did improve, although mitral regurgitation may cause inac-
curate calculations of forward LV stroke volumes. Which
modality is more accurate cannot be determined from this
study. Thermodilution measurements also cause inaccura-
cies in the setting of tricuspid regurgitation.
The Myosplint device was designed to alter a major com-
mon theme of chronic cardiomyopathy, LV dilation. Direct
LV reduction operations, such as LV aneurysmectomy and
the Batista procedure,3-6 have demonstrated early LV func-
tion improvements separate from associated procedures such
as valve repair or coronary artery bypass. However, the
Batista procedure in particular had a high early failure rate.
This was explained in part by the operation itself: a major
surgical procedure performed with cardiopulmonary bypass
that discarded a large segment of otherwise viable myocardi-
um and may have worsened preexisting diastolic dysfunc-
tion.6,20,21 Unlike the Batista operation, the current procedure
involves placement of the Myosplint device on a beating
heart, produces a measurable adjustable reduction in LV size,
recruits other areas of LV to improve function (like the Dor
procedure 22) rather than removing muscle, and likely does
not create major changes in diastolic function.8 However, fur-
ther studies are needed with the Myosplint device to more
precisely document changes in diastolic function.
By splinting the enlarged heart, we showed improved LV
function and reduced wall stress. By the law of Laplace, we
had predicted we would create a 20% reduction in wall
stress. Instead, we found a 39% reduction in end-systolic
wall stress and a 30% reduction in end-diastolic wall stress
acutely. What we observed was increased end-systolic wall
thickness and a greater decrease in the actual radius due to
improved LV systole accounting for the greater reduction in
wall stress than would have been predicted just on the basis
of change in radius mathematically. Whereas the Myosplint
changes occurred immediately and were maintained at 1
month, changes resulting from drug administrations have
been more modest and take longer to develop. Further stud-
ies are needed to determine whether the changes in wall
stress and the effects on the expression of stretch-activated
genes will also translate into beneficial molecular cytokine
and neurohormone effects that are equivalent to, or also
superior to, the effects of heart failure medications.
The device underwent significant evolution from con-
cept to a practical, easily deployed system. We were
encouraged that it could be easily applied on the beating
heart, with minimal localized bleeding and no sustained
arrhythmia. The Myosplint itself occludes the ventricular
needle holes, and the epicardial pads tamponade bleeding.
Furthermore, the pads disperse the ventricular compression
so that the likelihood of erosion is small.
Two limitations to the current study are the model itself and
measurements in the setting of a complicated LV shape
change. We chose the paced heart failure model to simulate
global idiopathic cardiomyopathy. However, because only 2
months had transpired from the beginning of pacing until study
termination, the myocardial interstitial changes, such as fibro-
sis, were not as pronounced as they would be in most patients
with chronic idiopathic cardiomyopathy. Therefore, systolic
Figure 4. In the Myosplint-treated animals, there was an immediate
improvement in LV ejection fraction as measured by 3-D echocar-
diography (from 20% to 36%). After 1 month of continued pacing, the
LV ejection fraction increase was the same as the acute change
(39% at 1 month), and both were significantly better than baseline
values. The ejection fraction remained low at 1 month in the con-
trol animals, which was significantly lower than Test group.
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and diastolic function in human beings may be different from
that in this experimental model, and Myosplint effects may be
blunted. Because of the severity of the model of congestive
heart failure as seen in our earlier developmental studies, we
did not do extended studies because we expected a high attri-
tion rate. Also, another series of animals will be studied with
additional measurements including myocardial oxygen con-
sumption and the construction of pressure-volume loops.
Because the Myosplint device creates a complicated LV
geometry, our method to calculate wall stress is new. The
circumferential wall stress of each anteroseptal and postero-
lateral lobe at the papillary muscle level was calculated sep-
arately by means of the law of Laplace for cylindrical cham-
bers; then the two values were averaged. This method of
averaging wall stress for two lobes has never been used or
validated, because there has been no need. Furthermore,
wall stress reduction at the level where the Myosplint was
placed may be different from that at different levels, such as
the one between two Myosplints where the shape change
was more modest. Because of these complexities, comput-
er-based finite element analysis may provide the best
method of calculating wall stresses throughout the LV wall.
As demonstrated by Ratcliffe and others,20 these models are
refined to the point that they provide a reasonably accurate
method of calculating myocardial wall stresses and cardiac
function. At this point, however, finite element methods are
not yet practical for analyzing empiric data generated in
investigational studies and would have limitations because
of heterogeneity in the ventricular wall, especially during
active contraction. To provide a straightforward yet accurate
method of analyzing changes in myocardial wall stress as a
result of a shape change, we have used a thin-walled cir-
cumferential wall stress calculation based on Laplace’s law
for cylindrical chambers. Laplace’s law makes the following
assumptions: (1) The muscle tissue behaves similar to non-
biologic materials and is therefore assumed to be elastic,
isotropic, and homogeneous; (2) the geometry of the LV is
a uniform-walled cylinder, sphere, or ellipsoid of revolu-
tion; (3) the stresses are uniform around the circumference
and are due exclusively to the LV pressure; and (4) radial
and bending stresses are ignored (thin walled). This analy-
sis uses the Laplace assumptions and makes the assumption
that the mid-chamber annular region of the ventricle is sub-
stantially cylindrically shaped before and after bilobular
shape change. Circumferential wall stress was chosen in this
study because it appears to be the most influential on car-
diac function; as other authors have described, the mid to
basal chamber region of the LV consists of primarily cir-
cumferential orientation of the muscle fibers.23
Measurements of LV volumes by 3-D echocardiogram
are more accurate than 2-D echocardiogram, because 3-D
echocardiogram does not require any geometric assump-
tions of the LV cavity. We previously reported the accuracy
of 3-D echocardiogram for determining LV volumes using
magnetic resonance imaging as a reference standard in our
patients after LV reconstruction surgery, another complex
LV shape change procedure.12,24,25 In human studies we
anticipate obtaining sequential 3-D echocardiogram and
magnetic resonance imaging studies in Myosplint-treated
patients. Unfortunately, we were not able to do magnetic
resonance imaging studies in animals.
In conclusion, this experiment served as “proof of concept”
of the Myosplint theory and answered the hypotheses that the
Myosplint device reduced LV wall stress, improved LV sys-
tolic function, and sustained these changes for 1 month. The
device was easily applied and consists of common biomateri-
als. Further testing in ischemic cardiomyopathy and studies to
include molecular markers of heart failure and measures of
diastolic function will provide further clarification. The device
will be studied in patients with dilated hearts as an adjunct for
those needing valve or bypass surgery or as sole surgical ther-
apy for patients with idiopathic cardiomyopathy.
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gant study that requires a lot of mathematical equations to figure
out. It is an interesting approach to fixing heart failure. Is it exact-
ly a 50:50 Myosplint or is there potentially a variation in where
you localize the pad? 
Dr. McCarthy. Currently the initial patient population is going
to be patients with a globular dilated cardiomyopathy. The mathe-
matics and the engineering get even more difficult when there is a
more discrete infarct in the left anterior descending distribution,
but making those changes will be a later area for investigation.
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past experience using transmural pledget-supported sutures to hold
papillary muscles in homograft mitral valve replacement. We were
facing problems of bleeding around the transmural suture and pro-
gressive perforation due to excess tension. I am afraid that you could
encounter the same problem in patients. Could you elaborate on that? 
Dr McCarthy. There have been 117 animal experiments to my
knowledge. The first thing that surgeons think when they look at
this is that the pads are going to tear, that there will be bleeding, or
that there will be some major trauma. We have seen none of that in
any of the animals nor in any of the patients whom we have treat-
ed. The needle that goes through is smaller than the braided ten-
sion member, which partially seals the hole. Also, the pads are
much larger and help tamponade some of the bleeding that might
have occurred at that point, but they also disperse some of the pres-
sure over a wider area. Therefore, I think there will be a very low
likelihood of the pads pulling through. 
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